Patent: 9,169,264
✉ Email this page to a colleague
Summary for Patent: 9,169,264
Title: | Spliceostatin analogs and methods for their preparation |
Abstract: | The present invention is directed to novel cytotoxic spliceostatin analogs and derivatives, to antibody drug conjugates thereof, and to methods for using the same to treat medical conditions including cancer. |
Inventor(s): | Subramanyam; Chakrapani (South Glastonbury, CT), Koehn; Frank Erich (Mystic, CT), Dirico; Kenneth John (Gales Ferry, CT), Eustaquio; Alessandra S. (Old Saybrook, CT), Green; Michael Eric (Boston, MA), He; Haiyin (Mahwah, NJ), He; Min (North Potomac, CT), O\'Donnell; Christopher John (Mystic, CT), Puthenveetil; Sujiet (North Attleboro, MA), Ratnayake; Anokha (Mystic, CT), Teske; Jesse Alexander (Westerly, RI), Yang; Hui Yu (Newton, MA) |
Assignee: | Pfizer Inc. (New York, NY) |
Application Number: | 14/069,057 |
Patent Claims: | see list of patent claims |
Details for Patent 9,169,264
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | RITUXAN | rituximab | Injection | 103705 | 11/26/1997 | ⤷ Try a Trial | 2032-11-05 |
Idec Pharmaceuticals Corp. | RITUXAN | rituximab | Injection | 103737 | 02/19/2002 | ⤷ Try a Trial | 2032-11-05 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 09/25/1998 | ⤷ Try a Trial | 2032-11-05 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 02/10/2017 | ⤷ Try a Trial | 2032-11-05 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |